Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. sd-rxRNA therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
Sep 25 - Sep 28, 201816th Annual Discovery on Target Conference
Sep 5, 2018 at 3:25 PM EDT20th Annual Rodman & Renshaw Global Investment Conference
Aug 14, 2018 at 4:30 PM EDTRXi Pharmaceuticals Second Quarter 2018 Conference Call